Get started
Author

Christine Radawski

Observed names: C Radawski, C. Radawski, Christine A. Radawski, Radawski, C, Radawski, C., Radawski, Christine
Observed institution: Eli Lilly (United States)
ORCID: 0000-0001-8487-6680
Observed ORCID: 0000-0001-8487-6680
OpenAlex ID: A5084417878
Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA
2019 · Christine Radawski, Mark C. Genovese, et al. · Rheumatology and Therapy · 90
PDF
Benefit–Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist
2015 · Christine Radawski, Elaine Morrato, et al. · Pharmacoepidemiology and Drug Safety · 28
Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania
2022 · Gwenda Simons, Jorien Veldwijk, et al. · Lara D. Veeken · 18
PDF
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance
2022 · Gwenda Simons, Ellen M Janssen, et al. · RMD Open · 14
PDF
The utility of real‐world evidence for benefit‐risk assessment, communication, and evaluation of pharmaceuticals: Case studies
2020 · Christine A. Radawski, Tarek A. Hammad, et al. · Pharmacoepidemiology and Drug Safety · 13
Treatment preferences for preventive interventions for rheumatoid arthritis: protocol of a mixed methods case study for the Innovative Medicines Initiative PREFER project
2021 · Marie Falahee, Gwenda Simons, et al. · BMJ Open · 11
PDF
Incorporation of a Benefit-Risk Assessment Framework Into the Clinical Overview of Marketing Authorization Applications
2015 · Anne Wolka, Margaret Warner, et al. · Therapeutic Innovation & Regulatory Science · 10
Maximum Acceptable Risk Estimation Based on a Discrete Choice Experiment and a Probabilistic Threshold Technique
2023 · Jorien Veldwijk, Rachael Lynn DiSantostefano, et al. · Patient · 9
PDF
Implementation of Structured Benefit-Risk Assessments in Marketing Authorization Applications: Lessons Learned
2016 · JuAn Wang, Anne Wolka, et al. · Therapeutic Innovation & Regulatory Science · 6
The Burden and Impacts of Mealtime Insulin from the Perspective of People with Diabetes
2023 · R. Paczkowski, J. L. Poon, et al. · Diabetes Therapy · 5
PDF
Exploring preferences of at-risk individuals for preventive treatments for rheumatoid arthritis
2022 · G Simons, K Schölin Bywall, et al. · Scandinavian Journal of Rheumatology · 2
Pos0591 Treatments to Prevent Rheumatoid Arthritis in First Degree Relatives: Demographic and Psychological Predictors of Risk Tolerances
2022 · G. Simons, E. Janssen, et al. · Annals of the Rheumatic Diseases · 2
PDF
P19 Assessing Heterogeneity in MAR: Methods and Models Beyond DCE
2022 · E Janssen, R DiSantostefano, et al. · Value in Health · 1
Op0160-hpr Preferences for Treatments to Prevent Rheumatoid Arthritis: Discrete Choice Survey of General Populations in United Kingdom, Germany, and Romania
2021 · G. Simons, J. Veldwijk, et al. · Annals of the Rheumatic Diseases · 1
PDF
Patient and Healthcare Professional Satisfaction, Acceptability, and Preference Experiences With Mirikizumab Administration for Ulcerative Colitis: An International Survey
2024 · David Clemow, Christine Radawski, et al. · Crohn s & Colitis 360
Can the General Public Be a Proxy for an “At-Risk” Group in a Patient Preference Study? A Disease Prevention Example in Rheumatoid Arthritis
2024 · R. L. DiSantostefano, G. Simons, et al. · Medical Decision Making
PDF
P1048 Mirikizumab administration experience from Ulcerative Colitis patients: Survey data from the LUCENT clinical program
2024 · D Clemow, C Radawski, et al. · Journal of Crohn s and Colitis
PDF
P781 Mirikizumab administration experience from Ulcerative Colitis patients and healthcare providers: Survey data from the LUCENT clinical program
2024 · D Clemow, C Radawski, et al. · Journal of Crohn s and Colitis
PDF
Op0276 Preferences for Treatments to Prevent Rheumatoid Arthritis: Discrete Choice Survey of Rheumatoid Arthritis Patients' First-degree Relatives in the United Kingdom and Germany.
2022 · G. Simons, J. Veldwijk, et al. · Annals of the Rheumatic Diseases
PDF
Exploring preferences of at-risk individuals for preventive treatments for rheumatoid arthritis
2022 · Simons, G, Bywall, K Schölin, et al. · Figshare
Structured Qualitative Benefit-Risk Assessment to Inform Go/No-Go Decisions for Phase III Testing of Pharmaceutical Products
2016 · Anne Wolka, Christine Radawski, et al. · Pharmaceutical Medicine
Patterns of medication use in the one year following initiation of DPP-4 inhibitors in the United States
2014 · C. Radawski, D.R. Nelson, et al. · Value in Health
PDF
Works count: 27
Citation count: 210
H-index: 8
I10-index: 7
Year
Topic
Type